Akunyili, Dora. 2005. «Counterfeit and Substandard Drugs, Nigeria’s Experience: Implications, Challenges, Actions and Recommendations.» Paper presented at World Bank Meeting for Key Interest Groups in Health, Washington, DC, March 11.

Baghdadi, G., J.C. Cohen, and E. Wondemagegnehu. 2005. «Measuring Transparency to Improve Good Governance in the Public Pharmaceutical Sector.» Working draft for field testing and revision, Departments of Medicines Policy and Standards and Ethics, Trade, Human Rights and Health Law, WHO, Geneva (October).

Baines, D.L., P. Brigham, D.R. Phillips, K.H. Tolley, and D.K. Whynes. 1997. «GP Fundholding and Prescribing in UK General Practice: Evidence from Two Rural, English Family Health Services Authorities.» Public Health 111 (5): 321–25.

Cercone, J., F. Duran-Valverde, and E. Munoz-Vargas. 2000. «Compromiso de gesti?n, rendici?n de cuentas y corrupci?n en los hospitals de la Caja Costarricense de Seguro Social.» Latin America Research Network Working Paper R-418, Inter-American Development Bank, Washington, DC.

Chapman, S., P. Durieux, and T. Walley. 2004. «Good Prescribing Practice.» In Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity, and Quality, eds. E. Mossialos, M. F. Mrazek and T. Walley. Buckingham, U. K.: Open University Press.

Cohen, Jillian Clare. 2003. «Key Pharmaceutical Policy Trends in Select Jurisdictions.» Report prepared for the Drug Strategy Review, Ministry of Health and Long-Term Care, Ontario, Canada (January).

Cohen, J. C., and J. Carikeo Montoya. 2001. «Using Technology to Fight Corruption in Pharmaceutical Purchasing: Lessons Learned from the Chilean Experience.» World Bank Institute, Washington, DC (February).

Cohen, J. C., J. A. Cercone, and R. Macaya. 2002. «Improving Transparency in Pharmaceutical Systems: Strengthening Critical Decision Points against Corruption.» World Bank, Washington, DC (October).

Cohen, J. C., and L. Esmail. 2005. «Creating Ethical Incentives for the Pharmaceutical Industry: Reality or Fantasy?» Paper presented at a seminar on «Self-Regulation in the Pharmaceutical Industry,» Basel Institute for Governance, Basel, April 21.

Enemark, U., A. Alban, and E. C. S. Vazquez. 2004. «Purchasing Pharmaceuticals.» Health, Nutrition, and Population Discussion Paper, World Bank, Washington DC (September).

FDA (U. S. Food and Drug Administration). 2000. «Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients» (July). http://www.fda.gov/cder/guidance/4011dft.htm (accessed August 18, 2006).

Gladwell, Malcolm. 2000. The Tipping Point: How Little Things Can Make a Big Difference. Boston: Little Brown & Company.

Henry, D., and J. Lexchin. 2002. «The Pharmaceutical Industry as a Medicines Provider.» Lancet 360: 1590–95.

IFPMA (International Federation of Pharmaceutical Manufacturers). 2002. «Counterfeit Medicines: The Role of Industry and Pharmacists.» http://www.ifpma.org/News (accessed March 20, 2006).

Klitgaard, R. 2000. «Subverting Corruption.» Finance and Development 37 (June): 2–5.

Kwon, S. 2006. «Politics and Process of Health Policy Change: The Case of Pharmaceutical Reform in Korea.» Seminar presentation to the Comparative Program on Health and Society, University of Toronto, April 5.

Management Sciences for Health in collaboration with the World Health Organization. 1997.

Managing Drug Supply, 2nd ed. West Hartford, CT: Kumarian Press Inc.

Marshall, I. 2001. «A Survey of Corruption Issues in the Mining and Mineral Sector.» Mining, Minerals and Sustainable Development Project, International Institute for Environment and Development, London.

McGuire, A., M. Drummond, and F. Rutten. 2004. «Reimbursement of Pharmaceuticals in the EU.» In Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity, and Quality, eds. E. Mossialos, M. F. Mrazek and T. Walley. Buckingham, U. K.: Open University Press.

McPake, B., D. Asiimwe, F. Mwesigye, M. Ofumbi, L. Ortenblad, P. Streefland, and others. 1999. «Informal Economic Activities of Public Health Workers in Uganda: Implications for Quality and Accessibility of Care.» Social Science and Medicine 49 (7): 849–65.

M?decins Sans Fronti?res. 2001. Fatal Imbalance: The Crisis in Research and Development for Drugs for Neglected Diseases. A Report by the MSF Access to Essential Medicines Campaign and the Drugs for Neglected Diseases Working Group, Geneva (November 30). http://www.accessmed-msf.org (accessed August 18, 2006).

Mossialos, E., M. Mrazek, and T. Walley, eds. 2004. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity, and Quality. Buckingham, U. K.: Open University Press.

Newton, P., S. Proux, M. Green, F. Smithuis, J. Rozendaal, and others. 2001. «Fake Artesunate in Southeast Asia.» Lancet 357 (9272): 1948–50.

Norris, P., A. Herxheimer, J. Lexchin, and P. Mansfield. 2005. «Drug Promotion: What We Know, What We Have Yet to Learn: Reviews of Materials in the WHO/HAI Database on Drug Promotion.» WHO, Geneva.

Parish, P. 1973. «Drug Prescribing – the Concern of All.» Journal of the Royal Society of Health 4: 213–17.

Pitts, P. 2005. «Moderator’s Guide.» Paper presented at the Center for Medicine in the Public Interest seminar «21st Century Health Care Terrorism: The Perils of International Drug Counterfeiting.» http://politicalcap.com/Counterfeiting_Report.pdf (accessed August 21, 2006).

Rodr?guez-Mongui?, R., and J. Rovira. 2005. «An Analysis of Pharmaceutical Lending by the World Bank.» Health and Nutrition Discussion Paper, World Bank, Washington, DC (January).

Satchwell, G. 2004. «A Sick Business: Counterfeit Medicines and Organised Crime.» The Stockholm Network, Stockholm.

Swenke, S. 2002. «Cross-Sector Analysis of Corruption: Summary Report.» Sectoral Perspectives on Corruption. Prepared for USAID, Democracy Conflict and Humanitarian Assistance, Washington, DC (November), http://www.usaid.gov/our_work/democracy_and_governance/publications/ac/sector/summary.doc. [accessed 08/18/06].

Taylor, Rosie, and Jim Giles. 2005. «Cash Interests Taint Drug Advice.» Nature 437 (October 20): 1080–81.

USAID (U. S. Agency for International Development). 1999. «A Handbook on Fighting Corruption.» Center for Democracy and Governance, USAID, Washington DC (February).

U. S. Pharmacopeial Convention Inc. 2005. «Mekong Region Takes Action against Fake Antimalarials.» U. S. Pharmacopeial Convention Inc., Rockville, MD.

Vian, T. 2003. «Corruption in the Health Sector in Albania.» Report prepared for the USAID/Albanian Civil Society Corruption Reduction Project, Management Systems International, Boston University School of Public Health, Boston, MA, http://www.bu.edu/actforhealth [accessed 01/05/06].

Vian, T. 2005. «Health Sector» In Fighting Corruption in Developing Countries, ed. B. I. Spector. Bloomfield, CT: Kumarian Press.

Watkins, C., I. Harvey, P. Carthy, L. Moore, E. Robinson, and R. Brawn, R. 2003. «Attitudes and Behavior of General Practitioners and Their Prescribing Costs: A National Cross-Sectional Survey.» Quality and Safety in Health Care 12: 29–34.

Wazana, Ashley. 2000. «Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?» Journal of the American Medical Association 283 (January 19): 373–380.

Wondemagegnehu, E. 1995. Counterfeit and Substandard Drugs in Myanmar and Viet Nam. Geneva: WHO.

World Bank. 2000. «Procurement of Health Sector Goods: Technical Note.» Health, Nutrition, Population, World Bank, Washington DC.

World Bank. 2006. «Albania: Health Sector Note.» Report 32612-AL, Europe and Central Asia/Health, Nutrition, Population, World Bank, Washington, DC (February).

WHO (World Health Organization). 1997. Quality Assurance of Pharmaceuticals: A Compendium of Guidelines and Related Materials. Geneva: WHO.

WHO (World Health Organization). 1998. «WHO Public-Private Roles in the Pharmaceutical Sector. Implications for Equitable Access and Rational Drug Use.» WHO/DAP. 97.12, WHO, Geneva.

WHO (World Health Organization). 2002. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva: WHO.

WHO (World Health Organization). 2003. «Expert Committee on Specifications for Pharmaceutical Preparations,» 37th report. WHO, Geneva.

WHO (World Health Organization). 2004a. «Equitable Access to Essential Medicines: A Framework for Collective Action.» WHO Policy Perspectives on Medicines 8 (March).

WHO (World Health Organization). 2004b. WHO Medicines Strategy: Countries at the Core 2004–2007. Geneva: WHO.

WHO (World Health Organization). 2004c. The World Medicines Situation. Geneva: WHO.

WHO (World Health Organization). 2005a. «Counterfeit Medicines.» http://www.who.int/mediacentre/factsheets/fs275/en/.

WHO (World Health Organization). 2005b. «Measuring Transparency to Improve Good Governance in the Public Pharmaceutical Sector.» Working draft for field testing and revision, WHO Departments of Medicines Policy and Standards and Ethics, Trade, Human Rights and Health Law (October), Geneva.

Данный текст является ознакомительным фрагментом.